INTERVENTION 1:	Intervention	0
Suramin and Paclitaxel	Intervention	1
suramin	CHEBI:180911	0-7
paclitaxel	CHEBI:45863	12-22
Suramin will be infused weekly over 30 minutes. Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin.	Intervention	2
suramin	CHEBI:180911	0-7
suramin	CHEBI:180911	87-94
hour	UO:0000032	53-57
hour	UO:0000032	110-114
paclitaxel	CHEBI:45863	127-137
Inclusion Criteria:	Eligibility	0
Patients must have histologically or cytologically confirmed stage IIIB or IV metastatic breast cancer (MBC)	Eligibility	1
breast cancer	DOID:1612	89-102
Prior chemotherapy:	Eligibility	2
Phase I: patients must have received prior paclitaxel or other taxanes in either the adjuvant or metastatic setting; prior chemotherapy, radiation or surgery must be completed at least 21 days before study entry; prior treatment with anthracyclines is not required	Eligibility	3
paclitaxel	CHEBI:45863	43-53
adjuvant	CHEBI:60809	85-93
surgery	OAE:0000067	150-157
Phase II: up to two prior chemotherapy regimens for stage IIIB or IV MBC; patients must have received prior paclitaxel or other taxanes in either the adjuvant or metastatic setting; prior chemotherapy, radiation or surgery must be completed at least 21 days before study entry; prior treatment with anthracyclines is not required	Eligibility	4
paclitaxel	CHEBI:45863	108-118
adjuvant	CHEBI:60809	150-158
surgery	OAE:0000067	215-222
Measurable disease (phase II)	Eligibility	5
disease	DOID:4,OGMS:0000031	11-18
No known brain metastases	Eligibility	6
brain	UBERON:0000955	9-14
Hormone receptor status:	Eligibility	7
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Not specified	Eligibility	8
Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2	Eligibility	9
group	CHEBI:24433	50-55
White blood cell (WBC) at least 3,000/mm^3	Eligibility	10
blood	UBERON:0000178	6-11
Absolute neutrophil count at least 1,000/mm^3	Eligibility	11
Platelet count at least 100,000/mm^3	Eligibility	12
platelet count	CMO:0000029	0-14
Hemoglobin at least 9.0 g/dL	Eligibility	13
hemoglobin	CHEBI:35143	0-10
Bilirubin no greater than 1.5 mg/dL	Eligibility	14
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) no greater than 2.5 times upper limit of normal	Eligibility	15
aspartate	CHEBI:29995	0-9
Creatinine no greater than 1.5 mg/dL	Eligibility	16
creatinine	CHEBI:16737	0-10
Left ventricular ejection fraction (LVEF) at least lower limit of normal	Eligibility	17
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
No symptomatic congestive heart failure	Eligibility	18
congestive heart failure	HP:0001635,DOID:6000	15-39
No unstable angina pectoris	Eligibility	19
angina pectoris	HP:0001681	12-27
No cardiac arrhythmia	Eligibility	20
arrhythmia	HP:0011675	11-21
Not pregnant or nursing	Eligibility	21
Negative pregnancy test	Eligibility	22
Fertile patients must use effective contraception	Eligibility	23
No history of allergic reactions attributable to compounds of similar chemical or biological composition to Cremophor	Eligibility	24
history	BFO:0000182	3-10
No concurrent uncontrolled illness that would preclude study compliance	Eligibility	25
No ongoing or active infection	Eligibility	26
active	PATO:0002354	14-20
No uncontrolled diabetes mellitus	Eligibility	27
diabetes mellitus	HP:0000819,DOID:9351	16-33
No psychiatric illness or social situations that would preclude study compliance	Eligibility	28
No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix	Eligibility	29
skin cancer	DOID:4159	79-90
carcinoma	HP:0030731,DOID:305	94-103
See Disease Characteristics	Eligibility	30
disease	DOID:4,OGMS:0000031	4-11
At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered	Eligibility	31
mitomycin	CHEBI:25357	71-80
No more than 2 prior chemotherapy regimens for this malignancy (phase II)	Eligibility	32
No concurrent steroids or hormones except the following:	Eligibility	33
Steroids to prevent hypersensitivity reactions prior to paclitaxel administration	Eligibility	34
hypersensitivity	GO:0002524,DOID:1205	20-36
paclitaxel	CHEBI:45863	56-66
Hormones for nondisease-related conditions (e.g., insulin for diabetes)	Eligibility	35
insulin	CHEBI:145810	50-57
At least 3 weeks since prior radiotherapy and recovered	Eligibility	36
radiotherapy	OAE:0000235	29-41
At least 3 weeks since prior surgery and recovered	Eligibility	37
surgery	OAE:0000067	29-36
No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients	Eligibility	38
immunodeficiency	HP:0002721	59-75
virus	BAO:0000232	76-81
No other concurrent investigational agents	Eligibility	39
Concurrent bisphosphonates (i.e., pamidronate or zoledronate) are allowed for the treatment of hypercalcemia or palliation of skeletal metastases	Eligibility	40
pamidronate	CHEBI:7903	34-45
hypercalcemia	HP:0003072,DOID:12678	95-108
Outcome Measurement:	Results	0
Percentage of Patients That Achieved Target Suramin Concentrations in Plasma	Results	1
target	BAO:0003064	37-43
suramin	CHEBI:180911	44-51
Target suramin concentration was considered achieved, if at least 5 of 6 patients achieved the target plasma concentration of 10-50 ÂµM over the duration of 8-48 hours when paclitaxel levels are therapeutic.	Results	2
target	BAO:0003064	0-6
target	BAO:0003064	95-101
suramin	CHEBI:180911	7-14
duration	PATO:0001309	144-152
paclitaxel	CHEBI:45863	172-182
Time frame: Up to 5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Suramin and Paclitaxel	Results	5
suramin	CHEBI:180911	17-24
paclitaxel	CHEBI:45863	29-39
Arm/Group Description: Suramin will be infused weekly over 30 minutes. Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin.	Results	6
suramin	CHEBI:180911	23-30
suramin	CHEBI:180911	110-117
hour	UO:0000032	76-80
hour	UO:0000032	133-137
paclitaxel	CHEBI:45863	150-160
Overall Number of Participants Analyzed: 9	Results	7
Measure Type: Number	Results	8
Unit of Measure: percent of patients  88	Results	9
percent	UO:0000187	17-24
Adverse Events 1:	Adverse Events	0
Total: 1/31 (3.23%)	Adverse Events	1
Adult respiratory distress syndrome (ARDS) 1/31 (3.23%)	Adverse Events	2
adult respiratory distress syndrome	DOID:11394	0-35
